FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – Europe 03/2024”.
The Monitor is a monthly published overview of venture capital trends in the European Healthcare & Life Sciences sector.
As of the end of March 2025 we identified the following current VC trends in Europe:
- Total Healthcare & Life Sciences funding reached EUR 3,713m (+55% vs. 2024)
- Biotech/Pharma received 35% of the total investment volume (EUR 1,316m) with metabolic disorders being the leading indication (30%)
- In March, Isomorphic Labs (United Kingdom) secured the highest transaction volume with EUR 536m, followed by Amboss (Germany) with EUR 240m and Augustine Therapeutics (Belgium) with EUR 78m
- The Series A financing round of EUR 536m for Isomorphic Labs (United Kingdom) is the largest ever early-stage TechBio financing round in Europe
- GV (United States) is the most active investor (by deal volume in 2025), followed by Alphabet (United States) and Thrive Capital (United States)
To access the full report, please click here.